Cyclerion Therapeutics, Inc. (CYCN)
NCM · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About Cyclerion Therapeutics, Inc.
Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 93K | 875K | 1.0M | 0.00 |
| Operating Income | -1.7M | -1.0M | -838K | -3.2M |
| Net Income | -324K | -976K | -799K | -3.2M |
| Diluted EPS | $-0.11 | $-0.30 | $nan | $-0.76 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 297K | 0.00 | 2.0M | 2.1M |
| Operating Income | -18.5M | -9.6M | -3.6M | -5.0M |
| Net Income | -44.1M | -5.3M | -3.1M | -3.5M |
| Diluted EPS | $-20.28 | $-2.25 | $-1.21 | $-1.11 |